Hosted on MSN

Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
The Diplomat

For Taiwan’s DPP, an Unprecedented ‘3-peat’ Depends on a Third Party

With Taiwan’s January 2024 presidential elections fast approaching, the field of candidates has taken shape. From the incumbent Democratic Progressive Party (DPP), Vice President William Lai seeks to ...
GEN

First DPP-4 Inhibitor in the U.S. Approved for Type 2 Diabetes

Merck & Co.’s drug indicated as a monotherapy and as an add-on to either metformin or TZDs. Merck & Co.’s Januvia™ (sitagliptin phosphate), which the company says is the first and only DPP-4 inhibitor ...
EurekAlert!

Breakthrough of DPP-1 Inhibitor in decreasing the exacerbation frequency of bronchiectasis (Lancet Respir Med)

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
The Diplomat

Taiwan’s DPP Wins Presidency, Falls Short in Legislature

Taiwanese Vice President Lai Ching-te, also known as William Lai, left, celebrates his victory with running mate Bi-khim Hsiao in Taipei, Taiwan, Jan. 13, 2024. Current Vice President Lai Ching-te ...